Benzinga | Feb 17, 2021 10:44AM EST

Ultragenyx's Dojolvi Ok'd In Canada For Genetic Metabolic Disorder

* Health Canada approves Ultragenyx Pharmaceutical Inc's (NASDAQ: RARE) Dojolvi (triheptanoin) as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD).

* LC-FAOD are a group of rare, genetic, metabolic deficiencies caused by defects in the enzymes needed to produce energy from fatty acids.

* Dojolvi is a highly purified, synthetic, 7-carbon fatty acid triglyceride specifically designed to provide medium-chain, odd-carbon fatty acids as an energy source and metabolite replacement.

* The treatment received U.S. approval in July last year.

* Price Action: RARE stock decreased 1.54% at $142.11 in trading session on last check Wednesday.